Pharma Exclusives Pressreleases
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Saturday, August 16, 2025Novo Nordisk today announced that the US Food and Drug Administration FDA has approved an additional indication for Wegovy semaglutide mg based on a supplemental New Drug Application
Hansa Biopharma announces supportive data from treatment with imlifidase prior to the administration of gene therapy for Duchenne muscular dystrophy
Saturday, August 02, 2025Hansa Biopharma AB Hansa Nasdaq Stockholm HNSA today announced topline results from three patients with Duchenne muscular dystrophy DMD treated with Hansas imlifidase prior to receiving Sareptas ELEVIDYS delandistrogene moxeparvovecrokl in the SRP tr...
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Saturday, August 02, 2025Rocheannounced today new fiveyear efficacy safety and durability data from the Phase III Portal study a longterm extension of the Phase III Archway study of Susvimo ranibizumab injection
Ryvu Announces Publication of Novel Target Discovery Data in Colorectal Cancer from the ONCO Prime Platform
Friday, August 01, 2025Ryvu Therapeutics a clinicalstage drug discovery and development company focused on novel therapies targeting emerging oncology indications announces the publication of data from its proprietary ONCO Prime target discovery
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Thursday, July 31, 2025Moderna Inctoday announced that the European Commission EC has granted marketing authorization for the updated formulation of the COVID vaccine Spikevax targeting the SARSCoV variant LP
Bayer submits registration applications for novel herbicide in four major markets
Wednesday, July 30, 2025Bayer advances its blockbuster pipeline submitting registration applications for icafolinmethyl in the European Union following completed applications in Brazil United States and Canada the company announced today
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
Wednesday, July 30, 2025Dr Falk Pharma GmbH a researchbased pharmaceutical company specializing in digestive and metabolic medicine Allianthera Suzhou Biopharmaceuticals Co Ltd and its affiliate Allianthera Boston Inc
Touchlight Introduces mbDNA™: A “Best-In-Class" Circular Single Stranded DNA (ssDNA) Platform Enabling Superior Gene Editing
Wednesday, July 30, 2025Touchlight a pioneer in cellfree DNA innovation is proud to announce the commercial launch of their new technology for nonviral gene editing mbDNA megabulb DNA Its novel circular singlestranded DNA ssDNA
Ofichem expands drug substance capabilities with acquisition of Meribel Pharma Solutions’ Uppsala site in Sweden
Tuesday, July 29, 2025Ofichem a European CDMO specialising in highquality active pharmaceutical ingredients APIs and integrated drug development and manufacturing services today announced the acquisition of Meribel Pharma Solutions site in Uppsala Sweden
European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
Friday, July 25, 2025Novo Nordisk today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion recommending an update of the Alhemo concizumab
